Methods and compositions comprising desmopressin in combination with alpha-adrenergic receptor antagonists
Combining desmopressin with alpha-adrenergic receptor antagonists addresses the challenge of achieving effective yet non-toxic plasma concentrations, providing safer and more effective treatment for nocturia and urinary frequency disorders by suppressing urinary urges with reduced side effects.
Patent Information
- Application Number
- JP2024134846
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2014-11-20
- Filing Date
- 2024-08-13
- Publication Date
- 2024-11-19
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing treatments for nocturia and urinary frequency disorders using desmopressin face challenges in achieving therapeutically effective plasma concentrations without causing toxicity, as high doses can lead to serious side effects such as hyponatremia.
Combining desmopressin with alpha-adrenergic receptor antagonists, administered in an overlapping period, to achieve effective suppression of urinary urges over intervals of 2 to 8 hours while maintaining plasma concentrations below toxic levels, typically less than 10 pg/ml, and using formulations like transmucosal, transdermal, or intradermal patches.
This combination therapy effectively reduces urinary frequency and side effects, allowing lower desmopressin doses, thereby enhancing safety and efficacy in treating nocturia and other urinary disorders.
Smart Images

Figure 2024161452000005 
Figure 2024161452000006 
Figure 2024161452000001
Abstract
Description
[Technical field]
[0001] The present invention provides methods and compositions for using desmopressin in combination with an alpha-adrenergic receptor antagonist, which are useful in the treatment of nocturia and other urinary frequency disorders. [Background technology]
[0002] Nocturia and other urinary frequency disorders affect a significant proportion of the human population. Patients with nocturia experience sleep interruptions due to the need to wake up at night to urinate. Patients with overactive bladder often experience urge incontinence, urgency, and high frequency of urination. Overactive bladder may be caused by uncontrolled contractions of the smooth muscle fiber bundles that make up the muscular layer of the bladder (detrusor) during the filling phase of the bladder and is more prevalent in older adults.
[0003] Compositions and methods for treating nocturia and other frequent urination disorders have been described. For example, Patent Document 1, Patent Document 2, and Patent Document 3 describe pharmaceutical compositions and methods using low doses of desmopressin. Patent Document 4 describes the treatment of nocturia and other frequent urination disorders, for example, using transdermal administration of desmopressin. Patent Document 5 also describes the treatment of nocturia and other frequent urination disorders, for example, using intranasal administration of desmopressin. [Prior art documents] [Patent documents]
[0004] [Patent Document 1] U.S. Patent No. 7,579,321 [Patent Document 2] U.S. Patent No. 7,799,761 [Patent Document 3] U.S. Patent No. 8,143,225 [Patent Document 4] US Patent Application Publication No. US2009 / 0042970 [Patent Document 5] US Patent Application Publication No. US2012 / 0015880 Summary of the Invention [Problem to be solved by the invention]
[0005] One of the challenges in treating nocturia and other frequent urination disorders with desmopressin is to achieve a therapeutically effective and non-toxic plasma concentration of desmopressin.Administering excessively large amounts of desmopressin can cause serious side effects such as hyponatremia, which can lead to seizures or patient death.Therefore, there is a need for compositions and methods that use lower dosages of desmopressin to improve safety profile and / or improve efficacy.The present invention addresses this need and provides other related advantages. [Means for solving the problem]
[0006] The present invention provides methods and compositions for using desmopressin in combination with an alpha-adrenergic receptor antagonist. This combination therapy provides benefit to human subjects suffering from disorders associated with or characterized by unwanted bladder emptying or frequent urination. Such humans may suffer from excessive urine production, inadequate urine concentration, low urine osmolality, excessive urination frequency (e.g., excessive urination frequency associated with central diabetes insipidus), adult primary nocturnal enuresis, nocturia, overactive bladder syndrome (OAB), urgency and frequency upon awakening, urinary incontinence, or unwanted urine production resulting in resting urine leakage or urine leakage due to exertion or stress. Desmopressin and an alpha-adrenergic receptor antagonist are administered to the subject such that both are physiologically active during an overlapping period. Representative alpha-adrenergic receptor antagonists include, for example, alfuzosin, amosulalol, arotinolol, dapiprazole, doxazosin, ergoloid mesylates, fenspiride, idazoxan, indoramin, labetalol, naftopidil, nicergoline, prazosin, silodosin, tamsulosin, terazosin, tolazoline, yohimbine, phenoxybenzamine, phentolamine, typical and atypical antipsychotics, atipamezole and their pharmaceutically acceptable salts.In certain embodiments, the method optionally further comprises administering a 5-alpha reductase inhibitor.
[0007] Thus, in one aspect of the invention, a method is provided for suppressing the need to urinate in a human subject for an interval of about 2 hours to about 8 hours or less. The method comprises administering to a human subject in need thereof effective amounts of desmopressin and an alpha-adrenergic receptor antagonist such that both are biologically active during the overlap period. The desmopressin and antagonist components may be administered separately or together. Typically, the desmopressin component is taken shortly before the start of the micturition avoidance period, for example about 1 hour and 30 minutes. The antagonist component may be taken simultaneously with or some time before the administration of desmopressin. The dosage and / or dosing regimen of the desmopressin and / or alpha-adrenergic receptor antagonist may be adjusted such that the method suppresses the need to urinate in a human subject for an interval of about 4 hours to about 7 hours. The desmopressin is administered at a dosage such that the subject does not suffer from hyponatremia (a harmful condition in which the sodium concentration in the subject's plasma is excessively low, for example less than about 135 mmol / L). Hyponatremia is avoided when the maximum dose of desmopressin in blood is less than 10 pg / ml, preferably less than 5 pg / ml, most preferably less than 5 pg / ml, e.g., 2 or 3 pg / ml. Severe hyponatremia can lead to electrolyte abnormalities that can cause cardiac arrhythmias, heart attacks, attacks, and / or strokes. Preferably, the antagonist is administered at a dosage less than that indicated on the label (of the approved drug) or at the dosage recommended for use solely for this purpose in clinical practice to treat OAB. This results in a reduction in the side effects of such alpha-adrenergic receptor antagonists. Combination therapy has been shown to effectively treat nocturia reliably and safely. In certain embodiments, the method optionally further comprises administering a 5-alpha reductase inhibitor. In another aspect of the invention, a method is provided for safely inducing an antidiuretic effect in a human subject for a short interval. The method includes administering to a human subject in need thereof effective amounts of desmopressin and an alpha-adrenergic receptor antagonist, such that both are biologically active during the overlap period.In certain embodiments, the method optionally further comprises administering a 5-alpha reductase inhibitor, e.g., such that each of the desmopressin, alpha-adrenergic receptor, and 5-alpha reductase inhibitor is physiologically active during the overlap period.
[0008] In another aspect of the present invention, a pharmaceutical composition is provided that includes desmopressin, an alpha-adrenergic receptor antagonist, and a pharma- ceutical acceptable carrier. In certain embodiments, the pharmaceutical composition is formulated for transmucosal administration to a human subject, for example, buccal or nasal administration. In other embodiments, the composition is formulated as a transdermal or intradermal patch. In other embodiments, the alpha-adrenergic receptor antagonist is taken orally while the desmopressin is taken transmucosally, for example, sublingually or intranasally.
[0009] That is, the gist of the present invention is [1] A method for suppressing the urge to urinate in an adult human subject for an interval of about 2 hours to about 8 hours or less, comprising administering to an adult human subject in need thereof effective, low doses of desmopressin and an alpha-adrenergic receptor inhibitor, such that both are physiologically active during the overlap period. [2] The method according to [1], which suppresses the urge to urinate in a human subject for an interval of about 4 hours to about 7 hours. [3] The method according to [1], wherein the antidiuretic effect is achieved over an interval of about 2 hours to about 6 hours or less. [4] The method according to [1], wherein the antidiuretic effect is achieved over an interval of about 4 hours to about 7 hours or less. [5] The method according to any one of [1] to [4], wherein the administration achieves a plasma concentration of desmopressin in the subject not exceeding 10 or 15 pg / mL. [6] The method according to any one of [1] to [4], wherein the administration achieves a plasma concentration of desmopressin in the range of about 0.5 pg / mL to about 5 pg / mL in the subject. [7] The method according to any one of [1] to [4], wherein the administration achieves a plasma concentration of desmopressin in the human subject in the range of about 0.5 pg / mL to about 2.5 pg / mL. [8] The method according to any one of [1] to [7], wherein desmopressin is administered transdermally, intradermally, or transmucosally through the oral or nasal mucosa. [9] The method according to any one of [1] to [7], wherein desmopressin is administered transdermally or intradermally.
[10] The method according to any one of [1] to [7], wherein desmopressin is administered intranasally.
[11] The method according to any one of [1] to [7], wherein desmopressin is administered sublingually through the oral mucosa.
[12] The method according to [9], wherein desmopressin is administered at an influx rate ranging from about 5 ng / hour to about 35 ng / hour.
[13] The method according to [9], wherein desmopressin is administered at an influx rate ranging from about 5 ng / hour to about 15 ng / hour.
[14] The method according to any one of [1] to
[13] , wherein the alpha-adrenergic receptor antagonist is alfuzosin, amosulalol, arotinolol, dapiprazole, doxazosin, ergoloid mesylates, fenspiride, idazoxan, indoramin, labetalol, naftopidil, nicergoline, prazosin, silodosin, tamsulosin, terazosin, tolazoline, yohimbine, phenoxybenzamine, phentolamine, atipamezole, or a pharma- ceutically acceptable salt thereof.
[15] The method according to any one of [1] to
[13] , wherein the alpha-adrenergic receptor antagonist is alfuzosin, doxazosin, idazoxan, prazosin, silodosin, tamsulosin, terazosin, tolazoline, yohimbine, or a pharma- ceutically acceptable salt thereof.
[16] The method according to any one of [1] to
[13] , wherein the alpha-adrenergic receptor antagonist is alfuzosin, doxazosin, prazosin, silodosin, tamsulosin, terazosin, tolazoline, yohimbine, or a pharma- ceutically acceptable salt thereof.
[17] The method according to any one of [1] to
[16] , wherein the alpha-adrenergic receptor antagonist is administered orally, transdermally, intradermally, or through the nasal or oral mucosa.
[18] The method according to any one of [1] to
[16] , wherein the alpha-adrenergic receptor antagonist is administered orally.
[19] The method according to any one of [1] to
[18] , wherein the alpha-adrenergic receptor antagonist is administered within 1 hour before or after the start of desmopressin administration.
[20] The method according to any one of [1] to
[19] , wherein the subject suffers from nocturia, urinary incontinence, enuresis, or diabetes insipidus.
[21] The method according to any one of [1] to
[19] , wherein the subject suffers from nocturia.
[22] The method according to any one of [1] to
[21] , wherein urine production in the human subject is restored within about 2 hours after administration of desmopressin is terminated.
[23] The method of [1], comprising administering to the adult human subject an alpha-adrenergic receptor antagonist daily for a period of at least one month, and administering desmopressin to the subject before bedtime.
[24] The method of [1], comprising administering to the adult human subject an alpha-adrenergic receptor antagonist at a dosage level lower than the minimum recommended dosage for treating BPH in the drug's labeling, and administering desmopressin to the subject before bedtime.
[25] The method of [1], comprising administering to the adult human subject a mixture of desmopressin and an alpha-adrenergic receptor antagonist at a dosage level lower than the minimum recommended dosage of the antagonist for the treatment of BPH before the subject sleeps.
[26] The method according to any one of [1] to
[25] , further comprising administering a 5-alpha reductase inhibitor.
[27] The method according to
[26] , wherein the 5-alpha reductase inhibitor is dutasteride, epristeride, finasteride, izonsteride, turosteride, AS-601811, FK143, TF-505, or a pharma- ceutically acceptable salt thereof.
[28] The method according to any one of [1] to
[27] , wherein the adult human subject is an adult male human.
[29] A pharmaceutical composition comprising desmopressin, an alpha-adrenergic receptor antagonist, and a pharma- ceutical acceptable carrier.
[30] The pharmaceutical composition according to
[29] , which is formulated for intranasal or sublingual administration to a human subject.
[31] The pharmaceutical composition according to
[29] or
[30] , wherein the alpha-adrenergic receptor antagonist is alfuzosin, amosulalol, arotinolol, dapiprazole, doxazosin, ergoloid mesylates, fenspiride, idazoxan, indoramin, labetalol, naftopidil, nicergoline, prazosin, silodosin, tamsulosin, terazosin, tolazoline, yohimbine, phenoxybenzamine, phentolamine, atipamezole, or a pharma- ceutical acceptable salt thereof. Regarding. Effect of the Invention
[0010] The present invention may provide methods and compositions that include desmopressin in combination with an alpha-adrenergic receptor antagonist. [Brief description of the drawings]
[0011] [Figure 1] 1 is a graph of desmopressin blood concentration and variable inflow rate versus time illustrating a seven hour operation of the device and method. [Diagram 2] 13 is a graph of desmopressin blood concentration and constant inflow rate versus time illustrating a seven hour operation of a device and method according to an alternative embodiment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0012] The present invention provides methods and compositions for using desmopressin in combination with an alpha-adrenergic receptor antagonist. This combination therapy provides benefit to subjects suffering from disorders associated with or characterized by unwanted bladder emptying or frequent urination. Such subjects may suffer from excessive urine production, inadequate urine concentration, low urine osmolality, excessive urination frequency (e.g., excessive urination frequency associated with central diabetes insipidus), adult primary nocturnal enuresis, urgency and frequency upon awakening, nocturia, overactive bladder syndrome (OAB), urinary incontinence, or unwanted urine production resulting in urinary leakage at rest or with exertion or stress. Desmopressin and an alpha-adrenergic receptor antagonist are administered to the subject such that both are physiologically active during the overlap period. The antagonists can be administered at doses less than those used in current clinical practice for the treatment of BPH.
[0013] Various aspects of the invention are described in several sections below; however, an aspect of the invention described in a particular section should not be construed as being limited to any particular section.
[0014] definition To facilitate the understanding of the invention, a number of terms and expressions are defined below.
[0015] The terms "a," "an," and "the" are used herein to mean "one or more" and include the plural forms unless the context requires otherwise.
[0016] As used herein, the term "effective amount" refers to an amount of a compound (e.g., a compound of the present invention) sufficient to produce a beneficial or desired result. An effective amount can be administered in one or more administrations, patches, or dosages, and is not intended to be limited to a specific formulation or route of administration. As used herein, the term "treating" includes any effect, such as reducing, decreasing, regulating, alleviating, or eliminating, that results in the improvement of a condition, disease, disorder, or the like, or the alleviation of symptoms thereof.
[0017] As used herein, the term "pharmaceutical composition" refers to a combination of an active agent with an inert or active carrier, making the composition particularly suitable for in vivo or in vitro therapeutic use.
[0018] As used herein, the term "pharmaceutical acceptable salt" refers to any pharmaceutically acceptable salt (e.g., acid or base) of the compound of the present invention that can provide the compound of the present invention or an active metabolite or a residue thereof when administered to a subject. As known to those skilled in the art, the "salt" of the compound of the present invention can be derived from inorganic or organic acids and bases. Examples of acids include, but are not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, ethanesulfonic acid, formic acid, benzoic acid, malonic acid, naphthalene-2 sulfonic acid, benzenesulfonic acid, and the like. Other acids, such as oxalic acid, may be used in preparing salts that are not themselves pharmaceutically acceptable but are useful as intermediates in obtaining the compounds of the present invention and their pharmaceutically acceptable acid addition salts.
[0019] Examples of bases include, but are not limited to, alkali metal (e.g., sodium) hydroxides, alkaline earth metal (e.g., magnesium) hydroxides, ammonia, and bases of the formula NW4 + (Wherein, W is C 1~4 (alkyl) and the like.
[0020] Examples of salts include, but are not limited to, acetate, adipate, alginate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptanoate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, 2-hydroxyethanesulfonate, lactate, maleate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phenylpropionate, picrate, pivalate, propionate, succinate, tartrate, thiocyanate, tosylate, undecanoate, and the like. Other examples of salts include Na + , NH4 + , and NW4 + (Wherein, W is C 1~4 Examples of suitable cations include the anions of the compounds of the present invention combined with suitable cations such as aryl, ... and alkyl groups.
[0021] For therapeutic uses, the salts of the compounds of the invention are expected to be pharma- ceutically acceptable. However, salts of acids and bases that are non-pharma-ceutically acceptable may also be useful, for example, in the preparation or purification of a pharma-ceutically acceptable compound.
[0022] The terms "subject" and "patient" are used interchangeably and refer to humans, particularly adult male humans.
[0023] Throughout the detailed description, where compositions and kits are described as having, including, or comprising specific components, or where processes and methods are described as having, including, or comprising specific steps, it is additionally anticipated that there are compositions and kits of the invention that consist essentially of, or consist of, the recited components, and that there are processes and methods according to the invention that consist essentially of, or consist of, the recited processing steps.
[0024] I. Treatment method The present invention provides a method of treatment using desmopressin in combination with an alpha-adrenergic receptor antagonist. This combination therapy provides benefit to subjects suffering from disorders associated with or characterized by undesirable and frequent urge to void from the bladder. As described above, such subjects may suffer from excessive urine production, inadequate urine concentration, low urine osmolality, OAB, excessive frequency of urination (e.g., excessive frequency of urination associated with central diabetes insipidus), adult primary nocturnal enuresis, urgency and frequency upon awakening, nocturia, urinary incontinence, or undesirable urine production resulting in urinary leakage at rest or urinary leakage due to exertion or stress. Desmopressin and the alpha-adrenergic receptor antagonist are administered to the subject such that both exert their biological activity during the overlap period. It is desirable that the administration of the alpha-adrenergic receptor antagonist and desmopressin produces a synergistic effect. Representative benefits from such synergy include an enhanced reduction in the subject's need to urinate and / or a reduced amount of desmopressin and / or antagonist required to achieve a therapeutic effect. Additionally, administering alpha-adrenergic receptor antagonists at lower doses compared to those used clinically to treat BPH means that the side effects of these drugs are reduced. In certain embodiments, the method optionally further comprises administering a 5-alpha reductase inhibitor.
[0025] In one aspect of the invention, a method is provided for suppressing the urge to urinate in a human subject for an interval of about 2 hours to about 8 hours or less. The method includes administering to a human subject in need thereof effective amounts of desmopressin and an alpha-adrenergic receptor antagonist, such that both are biologically active during the overlap period. The dosage and / or dosing regimen of desmopressin and / or the alpha-adrenergic receptor antagonist can be adjusted such that the method suppresses the urge to urinate in a human subject for a particular interval. For example, in certain embodiments, the method suppresses the urge to urinate in a human subject for an interval of about 4 hours to about 6 or 7 hours. Various embodiments of the method (e.g., dosages and routes of administration of desmopressin, alpha-adrenergic receptor antagonist, target patient populations, and representative examples of benefits of combination therapy) are described in the following sections. In certain embodiments, the method optionally further comprises administering a 5-alpha reductase inhibitor, e.g., such that each of the desmopressin, alpha-adrenergic receptor, and 5-alpha reductase inhibitor is physiologically active during the overlap period.
[0026] In another aspect of the invention, a method of inducing an antidiuretic effect in a human subject is provided. The method comprises administering to a human subject in need thereof, e.g., an adult male or female, effective amounts of desmopressin and an alpha-adrenergic receptor antagonist, such that both are biologically active during the overlap period. The method can be further characterized according to the interval over which the antidiuretic effect is provided. For example, in certain embodiments, the antidiuretic effect is achieved over an interval of about 4 hours to about 7 hours (or 8 hours) or less. In certain other embodiments, the antidiuretic effect is achieved over an interval of about 4 hours to about 6 hours. Various embodiments of the method (e.g., dosages and routes of administration of desmopressin, dosages and routes of administration of the alpha-adrenergic receptor antagonist, patient populations, and representative examples of benefits of combination therapy) are described in the following sections. In certain embodiments, the method optionally further comprises administering a 5-alpha reductase inhibitor, e.g., such that each of the desmopressin, alpha-adrenergic receptor, and 5-alpha reductase inhibitor is physiologically active during the overlap period.
[0027] In certain embodiments, the method comprises administering an alpha-adrenergic receptor antagonist to the subject daily (e.g., for a period of at least one month) to avoid the need to urinate overnight, and administering desmopressin to the subject before the subject goes to bed. In certain other embodiments, the method comprises administering an alpha-adrenergic receptor antagonist to the subject at a dosage level lower than the minimum recommended dose for treating BPH in the drug labeling, and administering desmopressin to the subject before the subject goes to bed. In yet other embodiments, the method comprises administering a mixture of desmopressin and an alpha-adrenergic receptor antagonist to the subject at a dosage level lower than the minimum recommended dose of said antagonist for treating BPH before the subject goes to bed.
[0028] Desmopressin The term "desmopressin" refers to 1-desamino-8-D-arginine vasopressin, including the free base form and its pharma- ceutically acceptable salts and hydrates. A representative example of a commercially available salt form is the acetate salt. Desmopressin, 1-desamino-8-D-arginine vasopressin monoacetate, also known as DDAVP, is described, for example, in U.S. Pat. No. 3,497,491 and is commercially available as a prescription drug sold, for example, under the trade names DesmoMelt, Stimate, Minirin® and DESMOSPRAY®. Desmopressin as an active pharmaceutical ingredient is also commercially available for formulation into new drug dosage forms and compositions. The dosage of desmopressin administered to a human subject can be selected based on the subject's body weight and the desired period for which the therapeutic effect is desired. The dosage can be characterized according to the plasma concentration of desmopressin achieved.
[0029] Thus, the methods of treatment described herein can be characterized according to the plasma concentration of desmopressin achieved. In certain embodiments, administration achieves a plasma concentration of desmopressin in the human subject that does not exceed 15 pg / mL. In certain other embodiments, administration achieves a plasma concentration of desmopressin in the human subject that ranges from about 0.2 pg / mL to about 5 pg / mL. In still other embodiments, administration achieves a plasma concentration of desmopressin in the human subject that ranges from about 0.5 pg / mL to about 2.5 pg / mL. In still other embodiments, administration achieves a plasma concentration of desmopressin in the human subject that ranges from about 0.5 pg / mL to about 1.5 pg / mL. In general, the amount of desmopressin that reaches the bloodstream from administration of a given dosage form should not exceed 2 ng / kg body weight, and can be as low as 0.5 ng / kg, 1.0 ng / kg, or 1.5 ng / kg.
[0030] Desmopressin can be administered using conventional routes of administration. For example, in certain embodiments, desmopressin is administered transdermally, intradermally, transmucosally, or possibly orally, although the variability of bioavailability in oral doses makes it difficult or impossible to consistently and reproducibly achieve very low blood levels. In certain other embodiments, desmopressin is administered transdermally, intradermally, or transmucosally. In yet other embodiments, desmopressin is administered transdermally. In yet other embodiments, desmopressin is administered intranasally.
[0031] When desmopressin is administered transdermally or intradermally, the method can be characterized according to the rate at which desmopressin passes through the skin of a human subject. For example, in certain embodiments, desmopressin is administered at a first influx rate sufficient to rapidly achieve a desired desmopressin plasma concentration (e.g., less than 5 pg / ml, preferably less than 2 pg / ml), and then at a second, lower influx rate sufficient to maintain the initially achieved plasma concentration for a desired interval (e.g., 6 hours). In certain embodiments, the method is further characterized by an influx range such that desmopressin is administered at an influx rate ranging from about 5 ng / hr to about 35 ng / hr. In yet other embodiments, desmopressin is administered at an influx rate ranging from about 5 ng / hr to about 35 ng / hr. In yet other embodiments, desmopressin is administered at an influx rate ranging from about 5 ng / hr to about 15 ng / hr.
[0032] The present invention anticipates the use of various devices and methods for administering desmopressin that have been previously described. See, for example, US Patent Application Publication Nos. US2009 / 0042970 and US2012 / 0015880, each of which is incorporated herein by reference. One device that may be used to administer desmopressin has a depot containing a solution of desmopressin in a pharma- ceutically acceptable carrier. An interface member for application to the patient's skin, such as a permeable pad for application to the skin or one or an array of microneedles, is in fluid communication with the depot. The device comprises various means for intradermally or transdermally delivering the desmopressin solution from the depot to the interface member and downstream into the patient's blood. The influx rate of desmopressin is controlled by setting the desmopressin concentration in the depot in conjunction with controlling either the flow rate of the solution from the depot, the flow rate of the solution to the interface member, or the flow rate of the solution from the interface member to the patient's body, or by utilizing some combination of these control points. In any event, the rate of inflow is controlled to sufficiently establish a blood desmopressin concentration in the patient just above the water channel activation threshold (e.g., in the range of 0.1 to about 2.5 pg / ml, advantageously no more than 1, 1.5, 2, or 2.5 pg / ml). The rate of inflow in any case would be inappropriate to induce a blood desmopressin concentration in the patient to a level greater than about 10 pg / ml. In order to establish a desired blood concentration at a reasonably predetermined time before the patient or device cuts off the flow of desmopressin, the inflow rate can be about 5, 10, 15, 20, 25, or 30-35 ng / hr (i.e., 5000, 10,000, 15,000, 20,000, 25,000, or 30,000-35,000 pg / hr), advantageously about 10-20 ng / hr or 20-35 ng / hr, and more advantageously about 5-15 ng / hr.
[0033] When desmopressin is used with an alpha-adrenergic receptor antagonist, it is desirable that the dosage of desmopressin and / or the duration of therapeutic plasma concentration of desmopressin required to achieve a therapeutic effect is less than when desmopressin is administered alone, and the urge to urinate is reduced compared to when the alpha-adrenergic receptor antagonist is administered alone. For example, in certain embodiments, the alpha-adrenergic receptor antagonist can reduce the need to urinate for a period of time after the plasma concentration of desmopressin falls below the threshold required to achieve antidiuresis (activation of water channels in the kidney). As another example, the physiological effect of the alpha-adrenergic receptor antagonist, in combination with less urine filling the bladder during the interval of induced antidiuresis, results in a reduced need to urinate in the patient.
[0034] For intradermal or transdermal administration, given the desired blood concentration and known clearance rate of desmopressin (half-life of about 1.5-2.0 hours), the influx rate of desmopressin is preferably set so that the patient reaches the desired low but above-threshold blood concentration in a reasonable time, e.g., less than 1 hour (faster is generally better), and is maintained within a low dose range just above the activation threshold (approximately 0.5-1.5 pg / ml) for the desired period of time (e.g., 2 hours for a trial, or 4-6 or 5-8 hours for treatment of nocturia). Termination of influx by an automatic or manual triggering mechanism built into the device, or by removing the device from skin contact, allows the patient's body to use normal drug clearance mechanisms to reduce the low concentration to an even lower concentration below the activation threshold.
[0035] The interface member of the device may include a desmopressin solution permeable membrane that defines a surface that contacts the patient's skin. The desmopressin solution permeable surface allows for delivery of desmopressin from the depot through or to the patient's skin. Intradermal delivery is preferred for highest bioavailability and accuracy of delivery. Intradermal delivery allows for direct delivery to the vascularized compartment, resulting in rapid absorption into the systemic circulation and a corresponding rapid on / off effect. Although transdermal delivery is anticipated, the use of transdermal delivery is more susceptible to variable bioavailability due to the stratum corneum acting as a physical barrier to the drug reaching the epidermis and to the creation of a drug depot within the epidermis.
[0036] Thus, transdermal delivery methods and devices can benefit from approaches that reduce the effectiveness of the stratum corneum as a barrier to drug entry. The skin can also be "micropunctured" to introduce "micropassages" or "microcracks" across the stratum corneum to enhance subsequent transdermal delivery, for example, by one or more microneedles as described below.
[0037] The permeability of the stratum corneum can also be enhanced through the use of the following chemical penetration enhancers: dimethyl sulfoxide, dodecyl methyl sulfoxide, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, sodium laurate, sodium lauryl sulfate, cetyltrimethylammonium bromide, benzalkonium chloride, lecithin (see, e.g., U.S. Patent No. 4,783,450, all of which are incorporated herein by reference), 1-n-dodecylazacycloheptan-2-one (see, e.g., U.S. Patent Nos. 3,989,816; 4,316,893; 4,405,616; and 4,557,934, all of which are incorporated herein by reference), ethanol, propanol, octanol, Benzyl alcohol, lauric acid, oleic acid, valeric acid, isopropyl myristate, isopropyl palmitate, methyl propionate, ethyl oleate, propylene glycol, ethylene glycol, glycerol, butanediol, polyethylene glycol, polyethylene glycol monolaurate, urea, hydroxides (see, e.g., U.S. Pat. No. 6,558,695, which is incorporated herein by reference), dimethylacetamide, dimethylformamide, 2-pyrrolidone, 1-methyl-2-pyrrolidone, ethanolamine, diethanolamine, triethanolamine, salicylic acid, citric acid, succinic acid, and permeation enhancing peptides (see, e.g., U.S. Pat. No. 5,534,496, which is incorporated herein by reference).
[0038] An efficient means of desmopressin delivery from the depot to the skin is intradermal administration via an interface member that includes one or more microneedles that penetrate the stratum corneum of the patient and allow fluid communication between the depot and the epidermis, or allow direct contact with the surface or cavity of the desmopressin-coated or desmopressin-containing microneedles. The length and size of the microneedles are suitable for penetrating the stratum corneum while being small enough to cause little, if any, sensation to the patient. For example, a suitable length is about 0.3-1.5 mm, with about 0.8-1.1 mm being advantageous. An example of a single needle device is provided in U.S. Patent No. 6,939,324, which is incorporated herein by reference.
[0039] If more surface area or a more flexible patch is desired for delivery, multiple (e.g., an array) microneedles may be desirable. Each microneedle may have a channel that transports fluid from the depot to the end of the needle, or the microneedle may otherwise have a perforated or porous wall to allow fluid delivery from the depot. Alternatively, the microneedle may be coated with a desmopressin preparation or contain a film or matrix of desmopressin within the cavity or material structure of the microneedle itself, thereby providing a burst of desmopressin upon application to facilitate rapid attainment of the threshold activation concentration, and optionally allowing desmopressin liquid to pass through the needle to aid in attaining or maintaining the desired concentration.
[0040] Dissolvable microneedles are also anticipated for use, as they avoid the pain and / or irritation that can sometimes be caused by metal needles or piercing elements. For example, U.S. Patent No. 7,182,747 discloses "solid solution perforators" that may be adapted for use with the inventions disclosed herein. In contrast to conventional hollow needle technology, these microneedles are made from a solid matrix of dissolvable or biodegradable material that optionally holds one or more selected drugs and is formed into one or more perforators.
[0041] Another device for delivering desmopressin is a patch that the user applies before going to sleep or before any other interval of activity during which the patient desires to cease urine production. The patch may, but need not, include an active liquid flow control mechanism, for example, with a user-selectable timing feature, allowing the user to select the time during which normal urine production is desired to be inhibited (i.e., in the case of sleep, a time approximately equal to or less than the desired sleep time). The patient removes the patch from the packaging, sets the delivery time if necessary, and applies the patch to a site on the skin. Desmopressin delivery begins at the levels and rates described herein, and urine production is inhibited for the desired time. Normal urine production is rapidly restored when the flow control is shut off, the patch is removed, or the desmopressin depot is depleted. In a preferred simple version of the device, the amount of desmopressin in the depot and the inflow rate designed through depletion of the depot fix the delivery time, e.g., 5-7 hours, and the end of inflow simply corresponds to the depletion of the patch delivery. Thus, the patient can sleep, perhaps without having to be repeatedly awakened during sleep hours, or can engage in other activities without concern for involuntary urination.
[0042] The operation of a representative device will now be described with reference to the drawings.
[0043] FIG. 1 illustrates the operation of an exemplary embodiment of the present invention in treating a patient desiring to block urine production, for example in treating nocturia. A device for delivering low dosage / low variable inflow desmopressin to the patient according to the present invention is applied to the patient's skin and activated at 10:00 PM after the patient urinates. FIG. 1 shows exemplary and representative blood desmopressin concentrations and inflow rates for this patient at various times after application and activation of the device. At 1 hour (11:00 PM), the desmopressin inflow rate peaked at about 20 ng / hr and the patient's blood desmopressin concentration had risen to above about 1.0 pg / ml, i.e., a concentration sufficient to activate renal water channels and induce an antidiuretic effect (shown here as a blood concentration of about 0.8 pg / ml). At 2 hours (midnight), the inflow rate has decreased slightly but is still in the 20 ng / hr range and the blood desmopressin concentration has risen to about 1.5 pg / ml. These values slowly decline but remain relatively constant for the next 2.5-3 hours. After approximately 5 hours (3:00 AM), the influx rate has fallen to a level that cannot sustain an activating concentration of desmopressin. As the influx rate continues to fall, the blood desmopressin concentration falls below the water channel activation level and urine production begins (here approximately 3:45 AM). By 5:00 AM the blood concentration is below approximately 0.5 pg / ml and the influx rate has fallen to zero. By 6:00 AM the patient is awake and feels a normal urge to void as urine was produced during the final hour and a half or so of sleep. Antidiuretic intervals persist throughout sleep, with no or small urine production and no bothersome or sleep-interrupting urge to void. The influx rate of desmopressin and the blood concentration of desmopressin may be somewhat dependent on the dosage of alpha-adrenergic receptor antagonist administered to the patient. It is understood that the desmopressin and the alpha-adrenergic receptor antagonist may be administered to the patient in separate formulations, or the desmopressin and the alpha-adrenergic receptor antagonist may be mixed together to form a single formulation and administered to the patient.
[0044] FIG. 2 illustrates another exemplary embodiment of the present invention for treatment of shutting off urine production in a patient, for example, for treatment of nocturia. A device according to the present invention for delivering a constant influx of desmopressin at a low dosage is applied to the patient's skin. At 10:00 PM, the device is activated (if necessary) and the patient urinates. FIG. 2 illustrates an exemplary representative blood desmopressin concentration resulting from an infusion of a flow rate of about 10 ng / hr over about 5 hours from 10:00 PM to 3:00 AM, relative to the threshold blood concentration at which the antidiuretic effect of desmopressin is brought about. Within about 1 hour of the initiation of the infusion, the blood desmopressin concentration exceeds the threshold level and begins to exert its antidiuretic effect. Within about 2-3 hours, the blood concentration approaches a range of some stability (about 1.0-1.5 pg / ml), which persists for the remaining 5 hours of infusion until 3:00 AM. At this time, the infusion is discontinued (e.g., timed out or exhausted). Here, blood desmopressin concentration declines from clearance mechanisms according to the elimination half-life of the drug, dropping below the threshold approximately 2 hours later (5:00 AM). By 7:00 AM, the patient is producing urine and awakens to urinate. The rate of desmopressin influx and blood concentration of desmopressin may depend in part on the dosage of alpha-adrenergic receptor antagonist administered to the patient.
[0045] The above examples are for illustrative purposes only. Activation concentrations will of course vary between individuals, as will blood volume. The key principle in the operation of this device is that the antidiuretic effect is maintained by maintaining low desmopressin concentrations through a continuous low inflow of drug, and the interruption of inflow allows the body to quickly clear the drug and re-establish normal urine production, thus allowing safe control of the antidiuretic effect. This means that the patch device, when used as directed, enhances the safety of desmopressin administration with little or no risk of developing water toxicity.
[0046] In accordance with the present invention, the alpha-adrenergic receptor antagonist may be present in admixture with desmopressin in the patch device described above, or in an intranasal dosage form as disclosed below, but is preferably provided as a daily oral dose and is active in the plasma during the time that desmopressin is present.
[0047] An exemplary device for intranasal administration of desmopressin is a safety dispenser that induces an antidiuretic effect in members of a target patient population while reducing the risk of members of the patient population developing hyponatremia. The dispenser includes a reservoir having disposed therein a composition comprising a preparation of desmopressin and a nasal mucosal permeation enhancer in an amount sufficient to constitute multiple drug doses. The reservoir is in communication with an outlet and is equipped with a pump, preferably a disposable pump, preferably one that can be manually actuated, such as a squeeze bottle-actuated dispenser or a plunger pump attached to a glass bottle. The pump continuously dispenses multiple metered doses from the reservoir through the outlet in the form of a spray into one or both nostrils of the patient, allowing for a consistently sized dose to be deposited on the intranasal mucosa or other surface.
[0048] Each spray contains a large number of droplets, preferably with an average volume distribution ranging from 20 μm for D10 to about 300 μm for D90. This means that about 10% of the droplets have a diameter smaller than about 20 μm and 90% have a diameter smaller than 300 μm. Each spray dose is preferably by weight and with a desmopressin concentration such that it contains between 0.5 ng desmopressin per kilogram of patient weight and 75 ng desmopressin per kilogram of patient weight. The spray is characterized by a desmopressin bioavailability of greater than about 5%, i.e., about 5% to 25% of the active agent in the composition actually enters the patient's bloodstream and contributes to the drug effect, while the remainder is degraded, typically by digestion. Generally, the higher the bioavailability of the spray, the less desmopressin per spray needs to be delivered intranasally, and vice versa, although the goal is to achieve a target desmopressin maximum blood concentration (C ) in members of the patient population. max) more consistently.
[0049] The combined properties of the spray dispenser and the compositions it contains allow each dose of spray to effectively limit the concentration of desmopressin per kilogram produced in the patient's bloodstream to a relatively narrow range, thereby achieving a relatively consistent, time-limited antidiuretic period. In other words, each spray dose over time produces a relatively consistent desmopressin C concentration in the patient by drug transport across the intranasal mucosa. max The amount of drug delivered to the bloodstream in repeated doses from the same dispenser to the same person should differ by no more than 100%, preferably by less than 50%. The coefficient of variation of the dispenser is the same target C max C produced by continuous subcutaneous doses of desmopressin designed to achieve max Each intranasal dose of nebulizer delivered over time was similar to the coefficient of variation of the same target C max C produced by a subcutaneous bolus of desmopressin designed to achieve max Desmopressin C having a coefficient of variation within about 50%, more preferably within about 25%. max It is preferred that the level of the IL-1 receptor agonist (IL-1 receptor agonist) can be adequately established in the patient.
[0050] Target C max The value of C may vary depending on the duration of the antidiuretic interval that the dispensed composition is designed to induce and the dosage of the alpha-adrenergic receptor antagonist. For example, a product designed for a 7-8 hour urine production suppression interval should have a C of 15 + / - 3 pg / ml or less. max Thus, by way of example, a 7 hour product may have a bioavailability of 10% and a desmopressin loading of 0.75 μg or 750 ng per spray. This means that approximately 75 ng of drug will reach the patient's bloodstream, with a 70 kg (approximately 155 lb) adult receiving a dose of approximately 1.0 ng / kg in the bloodstream and a target C of less than about 5 pg / ml. maxAnother embodiment of the same product may have a bioavailability of 8% and a desmopressin loading of 2.0 μg or 2000 ng per spray, resulting in approximately 160 ng of drug in the patient's bloodstream as an effective dose of 160 ng / 75 kg or slightly more than 2 ng / kg, and a target C of less than about 10 pg / ml. max Another representative product may be designed for 3-4 hours of urinary continence and deliver a C of about 3 pg / ml or less. max may be delivered.
[0051] Alternatively, a single dispenser delivering, for example, 200 ng or 500 ng per spray, when used according to the package insert or physician's instructions, can function to achieve, for example, different antidiuretic periods in the same person, or the same antidiuretic period between adults of different weights, simply by varying the number of sprays delivered per administration event. Typically, the average urine volume per minute in the treated individual drops to less than about 4 ml / min, preferably less than about 1 ml / min, about 20 minutes to 1 hour after administration of the pharmaceutical composition of the present invention, and remains in this low range for a desired period of time, for example, 180 minutes, 240 minutes, 300 minutes, 360 minutes, or 420 minutes. About 20 minutes after administration, the average urine osmolality is greater than about 300 mOsmol / kg, and remains high for a period of time ranging up to 180 minutes, 240 minutes, 300 minutes, 360 minutes, or 420 minutes.
[0052] One of the important properties of intranasal administration is to consistently deliver maximum blood concentration over a relatively narrow time and dose range per spray, thus avoiding or minimizing accidental over-delivery, which may lead to longer than expected antidiuretic effects and the possibility of inducing hyponatremia. Consistent delivery, as used herein, should be interpreted to mean repeatable within a range similar to that observed when very low doses of desmopressin are administered by subcutaneous injection, or in some cases somewhat greater. Such consistency is more easily achieved by utilizing formulations with higher bioavailability, and thus bioavailability of at least 5%, preferably at least 10%, more preferably 15%, and preferably even higher, is preferred. Higher bioavailability is achieved by utilizing formulation techniques, particularly the use of penetration enhancers, and by chemical engineering of the spray compositions disclosed herein.
[0053] In one embodiment, the dispenser may further comprise a means for blocking the dispensing of a second desmopressin spray or series of sprays above a certain dose, e.g., approximately above a dose sufficient to result in a blood concentration above about 10-12 pg / ml, for a predetermined time interval after dispensing of the first dose. This may be accomplished passively, for example, as a result of the design of the spray mechanism as disclosed in U.S. Pat. No. 7,335,186, the disclosure of which is incorporated herein by reference. Alternatively, an active timer powered by a battery, mechanical spring, or compressed gas within the dispenser may be included, along with mechanisms known per se, designed to prevent a second dispense until a predetermined interval has elapsed, e.g., 8 hours, or any of 6-24 hours. Such mechanisms may prevent abuse of the product and may further minimize the possibility that a patient may accidentally or intentionally self-induce an overly prolonged antidiuresis.
[0054] Representative penetration enhancers for use in the formulation are the "Hsieh enhancers" commercially available from CPEX Pharmaceuticals (formerly Bentley) of Exeter, New Hampshire (see US 5,023,252). Preferred within the class of Hsieh enhancers useful in the preparation are those disclosed in US 7,112,561, and currently most preferred are those disclosed in US 7,244,703, such as cyclopentadecanolide, known in the art as CPE-215. Many other enhancers may also be used.
[0055] In some embodiments, the present invention provides the use of a safety dispenser to induce an antidiuretic effect. The dispenser and the desmopressin formulation may include any of the properties described herein. For example, in one embodiment, desmopressin C max C ranges from about 0.5 pg / ml to about 10.0 pg / ml. max is directly proportional to the amount of desmopressin administered intranasally. max The value of may vary depending on the duration of the antidiuretic interval that the dispensed composition is designed to induce and the dosage of the alpha-adrenergic receptor antagonist. For example, use of the safety dispensers described herein may result in antidiuresis of less than about 8 hours, less than about 6 hours, about 2-4 hours, or about 4-7 hours. Another representative use of the product is to provide a patient with a C of less than about 15 pg / ml, 10 pg / ml, 7 pg / ml, or 3 pg / ml or less. max The composition may be designed to deliver
[0056] Alpha-adrenergic receptor antagonists Alpha-adrenergic receptor antagonists are a class of medical drugs that are antagonists of alpha-adrenergic receptors. Alpha-adrenergic receptor antagonists are sometimes also referred to as alpha blockers. Representative alpha-adrenergic receptor antagonists include alfuzosin, doxazosin, idazoxan, prazosin, silodosin, tamsulosin, terazosin, tolazoline, yohimbine, and pharma- ceutically acceptable salts thereof. Each of these potentially suitable alpha-adrenergic receptor antagonists is briefly described below.
[0057] Alfuzosin Alfuzosin has the chemical name N-[3-[(4-amino-6,7-dimethoxy-2-quinazolinyl)methylamino]propyl]tetrahydro-2-furancarboxamide. Pharmaceutically acceptable salts of alfuzosin may be used. For example, the hydrochloride salt of alfuzosin is commercially available in tablet form under the trademark UROXATRAL®. Alfuzosin may be administered via routes known in the art, such as oral administration. The dosage of alfuzosin or a pharma-ceutically acceptable salt thereof to a patient may range, for example, from about 1 mg to about 100 mg per day. In certain embodiments, alfuzosin is administered (e.g., orally) in a daily dosage of about 1 mg to about 5 mg, about 5 mg to about 10 mg, about 10 mg to about 20 mg, about 20 mg to about 30 mg, about 30 mg to about 40 mg, about 40 mg to about 50 mg, about 50 mg to about 60 mg, about 60 mg to about 70 mg, about 70 mg to about 80 mg, about 80 mg to about 90 mg, or about 90 mg to about 100 mg. In certain other embodiments, alfuzosin is administered (e.g., orally) in a daily dosage of about 7.5 mg to about 12.5 mg, about 9 mg to about 11 mg, or about 9.5 mg to about 10.5 mg.
[0058] Doxazosin Doxazosin has the chemical name 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl]piperazine. Pharmaceutically acceptable salts of doxazosin (e.g., doxazosin hydrochloride or doxazosin mesylate) may be used. For example, doxazosin mesylate is commercially available in tablet form under the trademark CARDURA®. Doxazosin may be administered via routes known in the art, such as oral administration. Dosage of doxazosin or a pharma-ceutically acceptable salt thereof to a patient may range, for example, from about 0.1 mg to about 50 mg per day. In certain embodiments, doxazosin is administered in a daily dosage of about 0.1 mg to about 0.5 mg, about 0.5 mg to about 1.0 mg, about 1.0 mg to about 1.5 mg, about 1.5 mg to about 2.0 mg, about 2.0 mg to about 2.5 mg, about 2.5 mg to about 3.0 mg, about 3.0 mg to about 3.5 mg, about 3.5 mg to about 4.0 mg, about 4.0 mg to about 4.5 mg, about 4.5 mg to about 5.0 mg, about 5.0 mg to about 5.5 mg, about 5.5 mg to about 6.0 mg, about 6.0 mg to about 6.5 mg, about 6.5 ... g to about 7.0 mg, about 7.0 mg to about 7.5 mg, about 7.5 mg to about 8.0 mg, about 8.0 mg to about 9.0 mg, about 9.0 mg to about 10 mg, about 10 mg to about 12 mg, about 12 mg to about 14 mg, about 14 mg to about 16 mg, about 16 mg to about 18 mg, about 18 mg to about 20 mg, about 20 mg to about 25 mg, about 25 mg to about 30 mg, about 30 mg to about 35 mg, about 35 mg to about 40 mg, about 40 mg to about 45 mg, or about 45 mg to about 50 mg (e.g., orally).
[0059] Idazoxan Idazoxan has the chemical name 2-(2,3-dihydro-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole. Pharmaceutically acceptable salts of idazoxan (e.g., idazoxan hydrochloride) may be used. Idazoxan may be administered via routes known in the art, such as oral administration. The dosage of idazoxan or a pharma-ceutically acceptable salt thereof to a patient may range, for example, from about 0.1 mg to about 100 mg per day. In certain embodiments, idazoxan is administered in a daily dosage of about 0.1 mg to about 0.5 mg, about 0.5 mg to about 1.0 mg, about 1.0 mg to about 1.5 mg, about 1.5 mg to about 2.0 mg, about 2.0 mg to about 2.5 mg, about 2.5 mg to about 3.0 mg, about 3.0 mg to about 3.5 mg, about 3.5 mg to about 4.0 mg, about 4.0 mg to about 4.5 mg, about 4.5 mg to about 5.0 mg, about 5.0 mg to about 6.0 mg, about 6.0 mg to about 7.0 mg, about 7.0 mg to about 8.0 mg, or about 9.0 mg to about 10.0 mg. The dose is administered (e.g., orally) in the range of 0 mg, about 8.0 mg to about 9.0 mg, about 9.0 mg to about 10 mg, about 10 mg to about 15 mg, about 15 mg to about 20 mg, about 20 mg to about 25 mg, about 25 mg to about 30 mg, about 30 mg to about 35 mg, about 35 mg to about 40 mg, about 40 mg to about 45 mg, about 45 mg to about 50 mg, about 50 mg to about 60 mg, about 60 mg to about 70 mg, about 70 mg to about 80 mg, about 80 mg to about 90 mg, or about 90 mg to about 100 mg.
[0060] Prazosin Prazosin has the chemical name 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine. Pharmaceutically acceptable salts of prazosin may be used. For example, the hydrochloride salt of prazosin is commercially available in capsule form under the trademark MINIPRESS®. Prazosin may be administered via routes known in the art, such as oral administration. The dosage of prazosin or a pharma-ceutically acceptable salt thereof to a patient may range, for example, from about 0.1 mg to about 100 mg per day. In certain embodiments, prazosin is administered in a daily dosage of about 0.1 mg to about 0.5 mg, about 0.5 mg to about 1.0 mg, about 1.0 mg to about 1.5 mg, about 1.5 mg to about 2.0 mg, about 2.0 mg to about 2.5 mg, about 2.5 mg to about 3.0 mg, about 3.0 mg to 4.0 mg, about 4.0 mg to about 5.0 mg, about 5.0 mg to about 7.0 mg, about It is administered (e.g., orally) in the range of 7.0 mg to about 9.0 mg, about 9.0 mg to about 15 mg, about 15 mg to about 20 mg, about 20 mg to about 25 mg, about 25 mg to about 35 mg, about 35 mg to about 45 mg, about 45 mg to about 60 mg, about 60 mg to about 70 mg, about 70 mg to about 80 mg, about 80 mg to about 90 mg, or about 90 mg to about 100 mg.
[0061] Silodosin Silodosin has the chemical name 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carboxamide and is commercially available in capsule form under the trademark RAPAFLO®. Pharmaceutically acceptable salts of silodosin (e.g., silodosin hydrochloride) may be used. Silodosin may be administered via routes known in the art, such as oral administration. Patient dosages of silodosin or a pharma- ceutically acceptable salt thereof may range, for example, from about 0.1 mg to about 50 mg per day. In certain embodiments, silodosin is administered (e.g., orally) in a daily dosage range of about 0.1 mg to about 0.5 mg, about 0.5 mg to about 1.0 mg, about 1.0 mg to about 2.0 mg, about 2.0 mg to about 3.0 mg, about 3.0 mg to about 4.0 mg, about 4.0 mg to about 5.0 mg, about 5.0 mg to about 6.0 mg, about 6.0 mg to about 7.0 mg, about 7.0 mg to about 8.0 mg, about 8.0 mg to 10 mg, about 10 mg to about 15 mg, about 15 mg to about 20 mg, about 20 mg to about 25 mg, about 25 mg to about 35 mg, about 35 mg to about 45 mg, or about 45 mg to about 50 mg. In certain other embodiments, silodosin is administered (e.g., orally) in a daily dosage range of about 2.0 mg to about 6.0 mg, about 3.0 mg to about 5.0 mg, or about 3.5 mg to about 4.5 mg. In still other certain embodiments, silodosin is administered (e.g., orally) in a daily dosage range of about 6.0 mg to about 10 mg, about 7.0 mg to about 9.0 mg, or about 7.5 mg to about 8.5 mg.
[0062] Tamsulosin Tamsulosin has the chemical name 5-[(2R)-2-[[2-(2-ethoxyphenoxy)ethyl]amino]propyl]-2-methoxybenzenesulfonamide. Pharmaceutically acceptable salts of tamsulosin may be used. For example, the hydrochloride salt of tamsulosin is commercially available in capsule form under the trademark FLOMAX®. Tamsulosin may be administered via routes known in the art, such as oral administration. The dosage of tamsulosin or a pharma-ceutically acceptable salt thereof to a patient may range, for example, from about 0.05 mg to about 10 mg per day. In certain embodiments, tamsulosin is administered in a daily dosage of about 0.05 mg to about 0.10 mg, about 0.10 mg to about 0.20 mg, about 0.20 mg to about 0.30 mg, about 0.30 mg to about 0.40 mg, about 0.40 mg to about 0.50 mg, about 0.50 mg to about 0.60 mg, about 0.60 mg to about 0.70 mg, about 0.70 mg to about 0.80 mg, about 0.80 mg to about Tamsulosin is administered (e.g., orally) in a daily dosage range of about 0.90 mg, about 0.90 mg to about 1.0 mg, about 1.0 mg to about 1.5 mg, about 1.5 mg to about 2.0 mg, about 2.0 mg to about 2.5 mg, about 2.5 mg to about 3.0 mg, about 3.0 mg to about 4.0 mg, about 4.0 mg to about 5.0 mg, about 5.0 mg to about 6.0 mg, about 6.0 mg to about 8.0 mg, or about 8.0 mg to about 10 mg. In certain other embodiments, tamsulosin is administered (e.g., orally) in a daily dosage range of about 0.20 mg to about 0.60 mg, about 0.30 mg to about 0.50 mg, or about 0.35 mg to about 0.45 mg. In yet certain other embodiments, tamsulosin is administered (eg, orally) in a daily dosage range of about 0.60 mg to about 1.0 mg, about 0.70 mg to about 0.90 mg, or about 0.75 mg to about 0.85 mg.
[0063] Terazosin Terazosin has the chemical name 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine. Pharmaceutically acceptable salts of terazosin (e.g., terazosin hydrochloride or terazosin hydrochloride dihydrate) may be used. For example, the hydrochloride salt of terazosin is commercially available in capsule form under the trademark HYTRIN®. Terazosin may be administered via routes known in the art, such as oral administration. The dosage of terazosin or a pharma-ceutically acceptable salt thereof to a patient may range, for example, from about 0.1 mg to about 50 mg per day. In certain embodiments, terazosin is administered in a daily dosage of about 0.1 mg to about 0.5 mg, about 0.5 mg to about 1.0 mg, about 1.0 mg to about 1.5 mg, about 1.5 mg to about 2.0 mg, about 2.0 mg to about 2.5 mg, about 2.5 mg to about 3.0 mg, about 3.0 mg to about 3.5 mg, about 3.5 mg to about 4.0 mg, about 4.0 mg to about 4.5 mg, about 4.5 mg to about 5.0 mg, about 5.0 mg to about 5.5 mg, about 5.5 mg to about 6.0 mg, about 5.5 mg to about 6.0 mg, about 5.5 mg to about 7.0 mg, about 5.5 mg to about 7.0 mg, about 5.5 mg to about 8.0 mg, about 5.5 mg to about 8.0 mg, about 5.5 mg to about 9 ... In certain other embodiments, terazosin is administered (e.g., orally) in a daily dosage range of about 0.5 mg to about 1.5 mg, about 0.8 mg to about 1.2 mg, or about 0.9 mg to about 1.1 mg. In certain other embodiments, terazosin is administered (eg, orally) in a daily dosage range of about 1.5 mg to about 2.5 mg, about 1.8 mg to about 2.2 mg, or about 1.9 mg to about 2.1 mg.
[0064] Tolazoline Tolazoline has the chemical name 4,5-dihydro-2-(phenylmethyl)-1H-imidazole. Pharmaceutically acceptable salts of tolazoline (e.g., tolazoline hydrochloride) may be used. Tolazoline may be administered via routes known in the art, such as intravenous injection. The dosage of tolazoline or a pharma-ceutically acceptable salt thereof to a patient may range, for example, from about 1 mg / kg body weight to about 100 mg / kg body weight per 24 hour period. In certain embodiments, tolazoline is administered (e.g., intravenously) in a total daily dosage range of about 1 mg / kg to about 2 mg / kg body weight, about 2 mg / kg to about 3 mg / kg body weight, about 3 mg / kg to about 5 mg / kg body weight, about 5 mg / kg to about 7 mg / kg body weight, about 7 mg / kg to about 9 mg / kg body weight, about 9 mg / kg to about 10 mg / kg body weight, about 10 mg / kg to about 20 mg / kg body weight, about 20 mg / kg to about 30 mg / kg body weight, about 30 mg / kg to about 40 mg / kg body weight, about 40 mg / kg to about 60 mg / kg body weight, about 60 mg / kg to about 80 mg / kg body weight, or about 80 mg / kg to about 100 mg / kg body weight.
[0065] Yohimbine Yohimbine has the chemical name (16α,17α)-17-hydroxyyohimbine-16-carboxylic acid methyl ester. Pharmaceutically acceptable salts of yohimbine (e.g., yohimbine hydrochloride) may be used. Yohimbine may be administered via routes known in the art, such as oral administration. The dosage of yohimbine or a pharma-ceutically acceptable salt thereof to a patient may range, for example, from about 1 mg to about 50 mg per day. In certain embodiments, yohimbine is administered (e.g., orally) in a daily dosage range of about 1.0 mg to about 2.0 mg, about 2.0 mg to about 3.0 mg, about 3.0 mg to about 4.0 mg, about 4.0 mg to about 5.0 mg, about 5.0 mg to about 6.0 mg, about 6.0 mg to about 7.0 mg, about 7.0 mg to about 8.0 mg, about 8.0 mg to about 9.0 mg, about 9.0 mg to about 10 mg, about 10 mg to about 15 mg, about 15 mg to about 20 mg, about 20 mg to about 25 mg, about 25 mg to about 30 mg, about 30 mg to about 35 mg, about 35 mg to about 40 mg, about 40 mg to about 45 mg, or about 45 mg to about 50 mg.
[0066] Representative alpha-adrenergic receptor antagonists include, for example, amosulalol, arotinolol, dapiprazole, ergoloid mesylates, fenspiride, indoramin, labetalol, naftopidil, nicergoline, phenoxybenzamine, phentolamine, typical and atypical antipsychotics, atipamezole, and pharmaceutically acceptable salts thereof.
[0067] It is understood that the alpha-adrenergic receptor antagonist may be administered by conventional routes of administration known in the art. Certain routes of administration may be preferred for certain therapeutic agents, for example, if they have reduced first-pass metabolism or improved bioavailability. In certain embodiments, the alpha-adrenergic receptor antagonist is administered orally, transdermally, intradermally, or transmucosally, alone or in admixture with desmopressin. In yet other embodiments, the alpha-adrenergic receptor antagonist is administered orally.
[0068] This method can also be characterized according to the period between the start of administration of desmopressin and the start of administration of the alpha-adrenergic receptor antagonist. In certain embodiments, the first administration of desmopressin can coincide with the administration of the alpha-adrenergic receptor antagonist. Alternatively, the start of administration of desmopressin can be before or after the start of administration of the alpha-adrenergic receptor antagonist. In certain embodiments, the alpha-adrenergic receptor antagonist is administered within 1 hour from the start of administration of desmopressin. In certain embodiments, the alpha-adrenergic receptor antagonist is administered within 0.5 hours, within 1 hour, within 1.5 hours, or within 2 hours from the start of administration of desmopressin.
[0069] 5-alpha reductase inhibitors 5-alpha reductase inhibitors are a class of medical drugs that inhibit the activity of 5-alpha reductase. Representative 5-alpha reductase inhibitors include, for example, dutasteride, epristeride, finasteride, izonsteride, turosteride, AS-601811, FK143, TF-505, and pharma- ceutical acceptable salts thereof. Potentially suitable 5-alpha reductase inhibitors are briefly described below.
[0070] Dutasteride Dutasteride has the chemical name (5α,17β)-N-{2,5 bis(trifluoromethyl)phenyl}-3-oxo-4-azaandrost-1-ene-17-carboxamide and is commercially available as soft gelatin capsules under the trade name AVODART®. Pharmaceutically acceptable salts of dutasteride may be used. Dutasteride may be administered via routes known in the art, such as oral administration. The dosage of dutasteride or a pharma- ceutically acceptable salt thereof to a patient may range, for example, from about 0.1 mg to about 5 mg per day. In certain other embodiments, dutasteride is administered (e.g., orally) in a daily dosage range of about 0.1 to about 1 mg, about 1 mg to about 2 mg, about 2 mg to about 3 mg, about 3 mg to about 4 mg, or about 4 mg to about 5 mg. In certain other embodiments, dutasteride is administered (e.g., orally) in a daily dosage range of about 0.3 mg to about 0.7 mg. Presently preferred doses for adult males are less than the recommended dose for treating BPH, i.e., less than 0.5 mg / day, e.g., 0.1 to 0.3 or 0.4 mg / day.
[0071] Epristeride Epristeride has the chemical name 17β-(N-tert-butylcarboxamido)androsta-3,5-diene-3-carboxylic acid. A pharma- ceutically acceptable salt of epristeride may be used. The dosage of epristeride or a pharma- ceutically acceptable salt thereof to a patient may range, for example, from about 1 mg to about 500 mg. In certain embodiments, epristeride is administered in a daily dosage range of about 0.1 mg to about 1 mg, about 1 mg to about 2 mg, about 2 mg to about 5 mg, about 5 mg to about 10 mg, about 1 mg to about 50 mg, about 50 mg to about 100 mg, about 100 mg to about 150 mg, about 150 mg to about 200 mg, about 200 mg to about 250 mg, about 250 mg to about 300 mg, about 300 mg to about 350 mg, about 350 mg to about 400 mg, about 400 mg to about 450 mg, or about 450 mg to about 500 mg.
[0072] Finasteride Finasteride has the chemical name N-(1,1-dimethylethyl)-3-oxo-(5α,17β)-4-azaandrost-1-ene-17-carboxamide and is commercially available in tablet form under the trade name PROPECIA®. Pharmaceutically acceptable salts of finasteride may be used. Finasteride may be administered via routes known in the art, such as oral administration. The dosage of finasteride or a pharma- ceutically acceptable salt thereof to a patient may range, for example, from about 0.2 mg to about 20 mg per day. In certain other embodiments, finasteride is administered (e.g., orally) in a daily dosage range of about 0.2 mg to about 0.5 mg, about 0.5 mg to about 1 mg, about 1 mg to about 2 mg, about 2 mg to about 3 mg, or about 3 mg to about 5 mg. In certain other embodiments, finasteride is administered (e.g., orally) in a daily dosage range of about 1 mg to about 5 mg. The currently preferred adult male dose of finasteride in combination with desmopressin is less than the recommended dose of finasteride for treating BPH, i.e., less than 5 mg / day, e.g., about 1 to 3 or 4 mg / day. Less than 1.0 mg / day often works well and avoids most adverse side effects.
[0073] AS-601811 AS-601811 has the chemical name 4,8-dimethyl-2,3,5,6-tetrahydro-1H-benzo[c]quinolizin-3-one. Pharmaceutically acceptable salts of AS-601811 may be used. The dosage of AS-601811 or a pharma- ceutically acceptable salt thereof to a patient may range, for example, from about 1 mg to about 500 mg. In certain embodiments, AS-601811 is administered in a daily dosage range of about 1 mg to about 50 mg, about 50 to 100 mg, about 100 mg to about 150 mg, about 150 mg to about 200 mg, about 200 mg to about 250 mg, about 250 mg to about 300 mg, about 300 mg to about 350 mg, about 350 mg to about 400 mg, about 400 mg to about 450 mg, or about 450 mg to about 500 mg.
[0074] Isonsteride Izonsteride has the chemical name (4aR,10bR)-8-((4-ethyl-2-benzothiazolyl)thio)-1,4,4a,5,6,10b-hexahydro-4,10b-dimethylbenzo[f]quinolin-3-(2H)-one. A pharmaceutically acceptable salt of Izonsteride may be used. The dosage of Izonsteride or a pharmaceutically acceptable salt thereof to a patient may range, for example, from about 1 mg to about 500 mg. In certain embodiments, izonsteride is administered at a daily dosage ranging from about 1 to about 50 mg, about 50 to 100 mg, about 100 mg to about 150 mg, about 150 mg to about 200 mg, about 200 mg to about 250 mg, about 250 mg to about 300 mg, about 300 mg to about 350 mg, about 350 mg to about 400 mg, about 400 mg to about 450 mg, or about 450 mg to about 500 mg.
[0075] Turosteride Turosteride has the chemical name 1,3-diisopropyl-1-((4-methyl-3-oxo-4-aza-5 alpha-androstan-17 beta-yl)carbonyl)urea. Pharmaceutically acceptable salts of turosteride may be used. The dosage of turosteride or its pharma- ceutical acceptable salt to a patient may range, for example, from about 1 mg to about 500 mg. In certain embodiments, turosteride is administered in a daily dosage range of about 1 mg to about 50 mg, about 50 to 100 mg, about 100 mg to about 150 mg, about 150 mg to about 200 mg, about 200 mg to about 250 mg, about 250 mg to about 300 mg, about 300 mg to about 350 mg, about 350 mg to about 400 mg, about 400 mg to about 450 mg, or about 450 mg to about 500 mg.
[0076] FK143 FK143 has the chemical name 4-[3-[3-[bis(4-isobutylphenyl)methyl-amino]benzoyl]-1H-indol-1-yl]butyric acid. Pharmaceutically acceptable salts of FK143 may be used. The dosage of FK143 or its pharma- ceutical acceptable salt to a patient may range, for example, from about 1 mg to about 500 mg. In certain embodiments, FK143 is administered in a daily dosage range of about 1 mg to about 50 mg, about 50 to 100 mg, about 100 mg to about 150 mg, about 150 mg to about 200 mg, about 200 mg to about 250 mg, about 250 mg to about 300 mg, about 300 mg to about 350 mg, about 350 mg to about 400 mg, about 400 mg to about 450 mg, or about 450 mg to about 500 mg.
[0077] TF-505 TF-505 has the chemical name (-)-(S)-4-[1-[4-[1-(4-isobutylphenyl)butoxy]benzoyl]indolizin-3-yl]butyric acid. Pharmaceutically acceptable salts of TF-505 may be used. TF-505 may be administered via routes known in the art, such as oral administration. The dosage of TF-505 or a pharma-ceutically acceptable salt thereof to a patient may range, for example, from about 10 mg to 100 mg per day. In certain embodiments, TF-505 is administered (e.g., orally) in a daily dosage range of about 1 mg to about 10 mg, about 10 mg to about 20 mg, about 20 mg to about 30 mg, about 30 mg to about 40 mg, about 40 mg to about 50 mg, about 50 mg to about 60 mg, about 60 mg to about 70 mg, about 70 mg to about 80 mg, about 80 mg to about 90 mg, or about 90 mg to about 100 mg. In certain other embodiments, TF-505 is administered (e.g., orally) in a daily dosage range of about 25 mg to about 50 mg.
[0078] It is understood that more than one 5-alpha reductase inhibitor can be administered to a subject.For example, in certain embodiments, a pharma- ceutically acceptable salt of dutasteride and tamsulosin (e.g., tamsulosin hydrochloride) is administered to a subject.Capsules containing dutasteride and tamsulosin hydrochloride are commercially available under the trademark JALYN®.
[0079] Patient population The method is expected to provide therapeutic benefit to a human subject, preferably an adult male or female, often an adult over the age of 50, suffering from a disorder associated with or characterized by undesired bladder voiding. Exemplary disorders include nocturia, urinary incontinence, enuresis, and diabetes insipidus. In certain embodiments, the human subject suffers from nocturia.
[0080] Restoration of urine production This method may be further characterized according to the period of time required for the subject to resume normal urine production after the end of administration of desmopressin and an alpha-adrenergic receptor antagonist. It is important for the subject to resume normal urine production daily, so as to maintain proper fluid balance and eliminate waste products through urination. Thus, in certain embodiments, this method is further characterized in that urine production in the human subject is restored within about 2 hours after the end of administration of desmopressin. In certain embodiments, this method is further characterized in that urine production in the human subject is restored within about 1 hour after the end of administration of desmopressin.
[0081] Representative examples of benefits of combination therapy The methods and compositions are expected to provide a variety of benefits. One expected benefit is that when desmopressin is administered with an alpha-adrenergic receptor antagonist, the efficacy of continence in a human subject is improved compared to the efficacy observed when desmopressin is administered alone. In certain embodiments, when desmopressin is administered with an alpha-adrenergic receptor antagonist, the improvement in continence in a human subject can be 5%, 10%, 20%, 30%, 50%, 75%, 100% or more compared to the efficacy observed when desmopressin is administered alone.
[0082] Another potential benefit is the reduction of side effects associated with desmopressin administration. This is achieved primarily by allowing a lower dose of desmopressin to be used while still successfully achieving a reduction in urinary urge. In certain embodiments, when desmopressin is administered together with an alpha-adrenergic receptor antagonist, the side effects observed in human subjects are reduced more than when desmopressin is administered alone at a dose required to achieve the same therapeutic effect.
[0083] Administration of desmopressin and an alpha-adrenergic receptor antagonist can result in a synergistic effect, such as a synergistic improvement in urinary continence efficacy in a human subject. In certain embodiments, the synergistic improvement in efficacy is at least 5%, 10%, 15%, 20%, 25%, 30%, or more than the additive improvement in efficacy associated with administration of desmopressin and an alpha-adrenergic receptor antagonist. Clinical trials in the use of these types of combinations disclosed and claimed herein have already demonstrated superior efficacy and safety, and additional trials are ongoing.
[0084] II. Pharmaceutical Compositions and Dosage Considerations In another aspect of the present invention, a medical composition is provided that includes one or more therapeutic agents described herein and a pharma- ceutically acceptable carrier.The pharmaceutical composition can be specially formulated for administration in solid or liquid form, including those that are compatible with: (1) oral administration, e.g., drenches (aqueous or non-aqueous solutions or suspensions), tablets (e.g., buccal, sublingual, and / or targeted for systemic absorption), boluses, powders, granules, pastes for application to the tongue; (2) parenteral administration, e.g., by subcutaneous, intramuscular, intravenous, or epidural injection, e.g., as a sterile solution or suspension, or as a sustained release formulation; (3) topical application, e.g., as a cream, ointment, or sustained release patch or spray applied to the skin; (4) rectally or vaginally, e.g., as a vaginal suppository, cream, or foam; (5) sublingually; (6) ophthalmically; (7) transdermally; or (8) nasally.Further description of representative additives and formulations designed for specific administration routes is provided below.
[0085] In certain embodiments, the present invention provides a pharmaceutical composition comprising desmopressin, an alpha-adrenergic receptor antagonist, and a pharmaceutically acceptable carrier. The alpha-adrenergic receptor antagonist can be, for example, alfuzosin, amosulalol, arotinolol, dapiprazole, doxazosin, ergoloid mesylates, fenspiride, idazoxan, indoramin, labetalol, naftopidil, nicergoline, prazosin, silodosin, tamsulosin, terazosin, tolazoline, yohimbine, phenoxybenzamine, phentolamine, atipamezole, or a pharmaceutically acceptable salt thereof. In certain embodiments, the pharmaceutical composition is formulated for nasal administration to a human subject.
[0086] The expression "pharmacologically acceptable carrier" refers to a pharma- ceutically acceptable material, composition, or vehicle, such as, for example, a liquid or solid excipient, diluent, additive, manufacturing aid (e.g., lubricants, talc magnesium or calcium or zinc stearate, or stearic acid), or solvent encapsulating material, that is involved in carrying or transporting a compound of interest from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not harmful to the patient. Some examples of materials that can function as pharma- ceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and soybean oil; (10) (11) glycols, such as propylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethyl alcohol; (20) pH buffer solutions; (21) polyesters, polycarbonates, and / or polyanhydrides; and (22) other non-toxic compatible substances used in pharmaceutical formulations.
[0087] Wetting agents, emulsifiers, and lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweeteners, flavorings, preservatives, and antioxidants may also be present in the composition. Examples of pharmaceutically acceptable antioxidants include (1) water-soluble antioxidants such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, and sodium sulfite; (2) oil-soluble antioxidants such as ascorbic acid palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), lecithin, propyl gallate, and alpha-tocopherol; and (3) metal chelating agents such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, and phosphoric acid.
[0088] The formulations of the present invention include those suitable for oral, nasal, topical (including buccal and sublingual), rectal, vaginal and / or parenteral administration.The formulations may be conveniently presented in unit dosage form and may be prepared by any method well known in the pharmaceutical arts.The amount of active ingredient that may be combined with carrier materials to produce a single dosage form will vary depending on the host being treated, the particular mode of administration.The amount of active ingredient that may be combined with carrier materials to produce a single dosage form will generally be the amount of compound that produces a therapeutic effect.
[0089] Formulations of the present invention suitable for oral administration can be in the form of capsules, cachets, pills, tablets, lozenges (using a flavored base, usually sucrose and gum arabic or tragacanth), powders, granules, or as a solution or suspension in an aqueous or non-aqueous liquid, or as an oil-in-water or water-in-oil emulsion, or as an elixir or syrup, or as a pastille (using an inert base such as gelatin and glycerin, or sucrose and gum arabic), and / or as a mouthwash, and the like, each containing a predetermined amount of a compound of the present invention as the active ingredient. The compounds of the present invention can also be administered as a bolus, electuary, or paste.
[0090] In the solid dosage forms for oral administration of the invention (capsules, tablets, pills, dragees, powders, granules, lozenges, etc.), the active ingredient is mixed with one or more pharma- ceutically acceptable carriers, such as, for example, sodium citrate or dicalcium phosphate, and / or any of the following: (1) excipients or fillers, such as starch, lactose, sucrose, glucose, mannitol, and / or silicic acid; (2) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidone, sucrose, and / or gum arabic; (3) humectants, such as glycerol; (4) agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicic acids, and / or other suitable soluble or non-soluble ... Disintegrating agents such as salts and sodium carbonate; (5) dissolution retarders such as paraffin; (6) absorption enhancers such as quaternary ammonium compounds and surfactants such as poloxamers and sodium lauryl sulfate; (7) wetting agents such as cetyl alcohol, glycerol monostearate and non-ionic surfactants; (8) absorbents such as kaolin and bentonite clay; (9) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, zinc stearate, sodium stearate, stearic acid, and mixtures thereof; (10) coloring agents; and (11) sustained release agents such as crospovidone or ethylcellulose. In the case of capsules, tablets and pills, the pharmaceutical compositions may also contain buffering agents. Solid compositions of a similar type may also be employed as excipients in soft and hard shelled gelatin capsules using excipients such as lactose or milk sugar, as well as high molecular weight polyethylene glycols.
[0091] Tablets can be made by compression or molding, optionally with one or more accessory ingredients. Compressed tablets can be prepared using binders (e.g., gelatin or hydroxypropylmethylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium starch glycolate or cross-linked sodium carboxymethylcellulose), surface active agents or dispersants. Molded tablets can be made by molding a mixture of the powdered compound moistened with an inert liquid diluent in a suitable machine.
[0092] The liquid dosage form for oral administration of the compound of the present invention includes pharma- ceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.In addition to the active ingredient, the liquid dosage form may contain inert diluents commonly used in the art, such as water or other solvents, solubilizers and emulsifiers, such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil and sesame oil), glycerol, tetrahydrofuryl alcohol, polyethylene glycol and sorbitan fatty acid esters, and mixtures thereof.
[0093] Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, coloring, perfuming and preservative agents.
[0094] Suspensions may contain, in addition to the active compounds, suspending agents such as ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar, and tragacanth, and mixtures thereof.
[0095] The actual dosage level of the active ingredient in the pharmaceutical composition of the present invention may vary to obtain an amount, composition, and mode of administration of the active ingredient effective to achieve the desired therapeutic response in a particular patient, without causing toxicity to the patient. The dosage level selected will depend on a variety of factors, including the activity of the particular compound of the present invention or its salt being used, the route of administration, the time of administration, the excretion or metabolic rate of the particular compound being used, the rate and extent of absorption, the duration of treatment, other drugs, compounds and / or materials used in combination with the particular compound being used, the sex, weight, condition, overall health and medical history of the patient being treated, and similar factors well known in the medical arts.
[0096] A physician of ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician could start the dosage of the compound of the present invention used in the pharmaceutical composition at a level lower than that required to obtain the desired therapeutic effect, and gradually increase the dosage until the desired effect is achieved.
[0097] III. Medical Kit In another aspect of the invention, there is provided a kit for inhibiting the urge to urinate in a human subject or for inducing an antidiuretic effect in a human subject, comprising (i) instructions for use and (ii) desmopressin and (iii) an alpha-adrenergic receptor antagonist, either in admixture or separately, where the separate entities are administered in different ways, for example the antagonist orally and the desmopressin transmucosally or via a skin patch.
[0098] The above description describes several aspects and embodiments of the present invention, including methods of treatment, pharmaceutical compositions, and medical kits. All combinations and permutations of the aspects and embodiments are specifically contemplated in this patent application. EXAMPLES
[0099] The invention generally described herein will be more readily understood by reference to the following examples, which are included merely for the purpose of illustrating certain aspects and embodiments of the invention and are not intended to limit the invention.
[0100] Example 1 A clinical study was conducted to evaluate the effect of desmopressin in combination with an alpha-adrenergic receptor antagonist, either alone or in conjunction with a 5-alpha reductase inhibitor, on reducing the occurrence of nighttime voiding in patients. The experimental procedures and results are described below. The results show that desmopressin in combination with an alpha-adrenergic receptor antagonist, either alone or in conjunction with a 5-alpha reductase inhibitor, results in patients experiencing a greater percentage reduction in the occurrence of nighttime voiding than administration of desmopressin alone, administration of an alpha-adrenergic receptor antagonist alone, or administration of an alpha-adrenergic receptor antagonist in conjunction with a 5-alpha reductase inhibitor.
[0101] Part 1 Experimental Procedure Patients included in the study met the following criteria: (a) men or women aged 50 years or older who had experienced an average of at least two nocturnal voids per night for at least 6 months; (b) did not have any of the following conditions: congestive heart failure, diabetes insipidus, renal failure, hepatic failure, urinary incontinence, diseases requiring systemic steroids, malignancy within the past 5 years, sleep apnea, nephrotic syndrome, pelvic mass of unknown cause, bladder neurogenic dysfunction, had not undergone bladder surgery or radiation therapy, or were not pregnant or breastfeeding.
[0102] Patients received either (i) a 1.5 μg dose of desmopressin or (ii) a placebo as a nasal spray. The desmopressin nasal spray (or placebo) was administered daily before bedtime for a period of 12 weeks. In addition, patients who had previously been diagnosed with benign prostatic hyperplasia (BPH) and were taking an alpha-adrenergic receptor antagonist, either alone or with a 5-alpha reductase inhibitor, for the treatment of BPH continued to take the alpha-adrenergic receptor antagonist, either alone or with a 5-alpha reductase inhibitor, in the same dosage and frequency that they were using prior to enrollment in this study. All patients in this study who were taking an alpha-adrenergic receptor antagonist, either alone or with a 5-alpha reductase inhibitor, for the treatment of BPH had been taking an alpha-adrenergic receptor antagonist, either alone or with a 5-alpha reductase inhibitor, for at least 2 months prior to enrollment in this study and had experienced an average of at least 2 nocturnal voids per night prior to enrollment in this study. Desmopressin nasal spray was prepared by combining aliquots of stock emulsion and buffer as described below.
[0103] Stock Emulsion: To produce the stock emulsion, the following ingredients were added in parts by weight to a vessel equipped with a stir bar and mixed for 15 minutes at 60-65°C: (i) 180 parts of an aqueous solution of sorbitan monolaurate (Span-20) (12 mg / mL); (ii) 30 parts of an aqueous solution of polysorbate 20 (Tween-20) (2 mg / mL); (iii) 400 parts of an aqueous solution of cottonseed oil (26.6 mg / mL); (iv) 600 parts of an aqueous solution of cyclopentadecanolide (CPE-215) (40 mg / mL); and (v) water to produce a total batch size of 1,500 grams. After mixing, homogenize the preparation for 20-25 minutes using high speed mixing at 6500 RPM+ to produce a fine emulsion. Autoclave the solution to ensure sterility.
[0104] Buffer: To produce a citrate stock buffer, the following ingredients, by weight, were added to a vessel equipped with a stir bar and mixed for 5 minutes at 60-65° C.: (i) 6,200 parts water; (ii) 16 parts anhydrous citric acid in water (1.85 mg / mL); (iii) 76 parts sodium citrate, dihydrate in water (8.9 mg / mL); (iv) 104 parts polysorbate 20 (Tween-20) in water (12 mg / mL); and (v) water to produce a total batch size of 8,500 grams.
[0105] Desmopressin Stock Solution: To make the desmopressin stock solution, add 0.111 parts desmopressin acetate trihydrate to enough stock buffer to make 100.0 mL of solution and stir until all the desmopressin has dissolved to make a stock solution with a concentration of 100 ug desmopressin / mL. From this stock solution, a 30 ug / mL solution was prepared by dilution.
[0106] Desmopressin nasal spray: To produce the desmopressin nasal spray, an aliquot of the 30ug / mL solution was filtered to remove any bacterial contamination and diluted with an equal volume of stock emulsion to produce a sterile, preservative-free dosage form containing 15ug / mL desmopressin, pH 5.5, and 2% cyclopentadecanolide. These were bottled into sterile pump spray bottles fitted with a Pfeiffer APF pump sprayer that delivers 100μL per metered spray (i.e., 1.5pg desmopressin (i.e., 1500ng desmopressin) per spray). The liquid contains no detectable microorganisms.
[0107] Patients recorded the occurrence of nocturnal voiding during the study period. If they experienced a decrease in the average number of nocturnal voids during the treatment period after receiving treatment, they were designated "responders." Patients who did not experience a decrease in the average number of nocturnal voids during the treatment period were designated "non-responders."
[0108] Part 2 Results The results of the clinical trials are shown in Tables 1-4 below. Table 1 shows the results of administering desmopressin or placebo to BPH patients taking an alpha-adrenergic receptor antagonist alone or with a 5-alpha reductase inhibitor. The absolute response rate in BPH patients treated with desmopressin in combination with an alpha-adrenergic receptor antagonist, alone or with a 5-alpha reductase inhibitor, was 57% compared to 26% in the group treated with placebo (i.e., no desmopressin). This is a difference of 31%. [Table 1]
[0109] Table 2 shows the results of administering desmopressin or placebo to patients diagnosed with BPH who were not taking an alpha-adrenergic receptor antagonist alone or with a 5-alpha reductase inhibitor. The absolute response rate for BPH patients who received desmopressin (i.e., no alpha-adrenergic receptor antagonist or 5-alpha reductase inhibitor) was 43% compared with 29% in the placebo group (i.e., no desmopressin, alpha-adrenergic receptor antagonist, or 5-alpha reductase inhibitor), a difference of 14%. [Table 2]
[0110] Table 3 shows the results of administering desmopressin or placebo to patients who had not been diagnosed with BPH and therefore were not taking an alpha-adrenergic receptor antagonist alone or with a 5-alpha reductase inhibitor. The absolute response rate in non-BPH male patients taking desmopressin was 53% compared with 35% in the placebo group (i.e., no desmopressin), a difference of 18%. [Table 3]
[0111] In summary, patients receiving combination therapy (i.e., desmopressin combined with an alpha-adrenergic receptor antagonist, either alone or with a 5-alpha reductase inhibitor) had higher absolute response rates and higher relative response rates compared to those observed in (i) BPH patients taking desmopressin alone, and (ii) non-BPH male patients taking desmopressin alone, as shown below in Table 4. [Table 4]
[0112] Incorporation by Reference The entire disclosure of each of the patent documents and scientific articles referenced herein is incorporated by reference for all purposes.
[0113] Equivalent The present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. Therefore, the above embodiments should be considered in all respects as illustrative rather than limiting the present invention described herein. Therefore, the scope of the present invention is indicated not by the above description but by the appended claims, and all modifications that come within the meaning and scope of the claims are intended to be embraced within the scope of the present invention.
Claims
1. 1. A method for suppressing the urge to urinate in an adult human subject for an interval of about 2 hours to about 8 hours or less, comprising administering to an adult human subject in need thereof effective low doses of desmopressin and an alpha-adrenergic receptor inhibitor, both of which are physiologically active during the overlap period.
2. 10. The method of claim 1, wherein the method suppresses the urge to urinate in a human subject for an interval of about 4 hours to about 7 hours.
3. 10. The method of claim 1, wherein the antidiuretic effect is achieved over an interval of about 2 hours to about 6 hours or less.
4. 10. The method of claim 1, wherein the antidiuretic effect is achieved over an interval of no more than about 4 hours to about 7 hours.
5. 5. The method of any one of claims 1 to 4, wherein the administration achieves a plasma concentration of desmopressin in the subject not exceeding 10 or 15 pg / mL.
6. 5. The method of any one of claims 1 to 4, wherein said administration achieves a plasma concentration of desmopressin in said subject in the range of about 0.5 pg / mL to about 5 pg / mL.
7. 5. The method of any one of claims 1 to 4, wherein said administration achieves a plasma concentration of desmopressin in the human subject in the range of about 0.5 pg / mL to about 2.5 pg / mL.
8. 8. The method of any one of claims 1 to 7, wherein desmopressin is administered transdermally, intradermally, or transmucosally through the oral or nasal mucosa.
9. 8. The method of any one of claims 1 to 7, wherein desmopressin is administered transdermally or intradermally.
10. 8. The method of any one of claims 1 to 7, wherein desmopressin is administered intranasally.
11. 8. The method of any one of claims 1 to 7, wherein desmopressin is administered sublingually through the oral mucosa.
12. 10. The method of claim 9, wherein desmopressin is administered at an influx rate ranging from about 5 ng / hour to about 35 ng / hour.
13. 10. The method of claim 9, wherein desmopressin is administered at an influx rate ranging from about 5 ng / hour to about 15 ng / hour.
14. 14. The method of any one of claims 1 to 13, wherein the alpha-adrenergic receptor antagonist is alfuzosin, amosulalol, arotinolol, dapiprazole, doxazosin, ergoloid mesylates, fenspiride, idazoxan, indoramin, labetalol, naftopidil, nicergoline, prazosin, silodosin, tamsulosin, terazosin, tolazoline, yohimbine, phenoxybenzamine, phentolamine, atipamezole, or a pharma- ceutically acceptable salt thereof.
15. 14. The method of any one of claims 1 to 13, wherein the alpha-adrenergic receptor antagonist is alfuzosin, doxazosin, idazoxan, prazosin, silodosin, tamsulosin, terazosin, tolazoline, yohimbine, or a pharma- ceutically acceptable salt thereof.
16. 14. The method of any one of claims 1 to 13, wherein the alpha-adrenergic receptor antagonist is alfuzosin, doxazosin, prazosin, silodosin, tamsulosin, terazosin, tolazoline, yohimbine, or a pharma- ceutically acceptable salt thereof.
17. 17. The method of any one of claims 1 to 16, wherein the alpha-adrenergic receptor antagonist is administered orally, transdermally, intradermally, or through the nasal or oral mucosa.
18. 17. The method of any one of claims 1 to 16, wherein the alpha-adrenergic receptor antagonist is administered orally.
19. 19. The method of any one of claims 1 to 18, wherein the alpha-adrenergic receptor antagonist is administered within 1 hour before or after the start of desmopressin administration.
20. 20. The method of any one of claims 1 to 19, wherein the subject suffers from nocturia, urinary incontinence, enuresis, or diabetes insipidus.
21. 20. The method of any one of claims 1 to 19, wherein the subject suffers from nocturia.
22. 22. The method of any one of claims 1 to 21, wherein urine production in the human subject is restored within about 2 hours after administration of desmopressin has ended.
23. 10. The method of claim 1, comprising administering to said adult human subject an alpha-adrenergic receptor antagonist daily for a period of at least one month, and administering desmopressin to said subject before bedtime.
24. 2. The method of claim 1, comprising administering to the adult human subject an alpha-adrenergic receptor antagonist at a dosage level that is lower than the minimum recommended dose for treatment of BPH in the drug's labeling, and administering desmopressin to the subject before bedtime.
25. 13. The method of claim 1, comprising administering to the adult human subject a mixture of desmopressin and an alpha-adrenergic receptor antagonist prior to the subject's sleep at a dosage level that is lower than the minimum recommended dosage of the antagonist for the treatment of BPH.
26. 26. The method of any one of claims 1 to 25, further comprising administering a 5-alpha reductase inhibitor.
27. 27. The method of claim 26, wherein the 5-alpha reductase inhibitor is dutasteride, epristeride, finasteride, izonsteride, turosteride, AS-601811, FK143, TF-505, or a pharma- ceutically acceptable salt thereof.
28. 28. The method of any one of claims 1 to 27, wherein the adult human subject is an adult male human.
29. A pharmaceutical composition comprising desmopressin, an alpha-adrenergic receptor antagonist, and a pharma- ceutically acceptable carrier.
30. 30. The pharmaceutical composition of claim 29, formulated for intranasal or sublingual administration to a human subject.
31. 31. The pharmaceutical composition of claim 29 or 30, wherein the alpha-adrenergic receptor antagonist is alfuzosin, amosulalol, arotinolol, dapiprazole, doxazosin, ergoloid mesylates, fenspiride, idazoxan, indoramin, labetalol, naftopidil, nicergoline, prazosin, silodosin, tamsulosin, terazosin, tolazoline, yohimbine, phenoxybenzamine, phentolamine, atipamezole, or a pharma- ceutically acceptable salt thereof.
Citation Information
Patent Citations
Methods and devices for desmopressin drug delivery
US20090042970A1
Intranasal desmopressin administration
US20120015880A1
Pharmaceutical compositions including low dosages of desmopressin
US7579321B2
Pharmaceutical compositions including low dosages of desmopressin
US7799761B2
Pharmaceutical compositions including low dosages of desmopressin
US8143225B2
